Richmond, March 05, 2024 (GLOBE NEWSWIRE) -- According to a research report "ADC Contract Manufacturing Market”, by Linker (Cleavable Linker, Non-Cleavable Linkers, and Others), Application (Myeloma, Lymphoma, Breast Cancer, and Others), End User (Pharmaceutical Companies, Biotechnology Companies, and Others) and Region - Global Forecast to 2030.
Global ADC Contract Manufacturing Market Report Scope:
| Report | Details |
| Market size value in 2023 | USD 9.5 Billion |
| Market size value in 2030 | USD 27.4 Billion |
| CAGR (2023-2030) | 14.2% |
| Forecast Period | 2023–2030 |
| Historic Data | 2019 |
| Forecast Units | Value (USD Million/USD Billion) |
| Segments Covered | Linker, Application, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and RoW |
| |
| |
| Sample of Companies Covered |
|
| |
|
Download the Sample - https://www.marketdigits.com/request/sample/4552
TOC Covers in Depth & Breath on ADC Contract Manufacturing Market
170 - Market Data Tables
65 - List of Figures
225 – Pages
The report includes Vendor Assessment (Company Profiles, Market Positioning, Strategies, Recent Developments, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & Economic Impact), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional FootPrint by MarketDigits.
Market Overview
The ADC (Antibody-Drug Conjugate) contract manufacturing market has observed significant growth, driven by the increasing demand for targeted cancer therapies. ADCs represent a promising class of biopharmaceuticals designed to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues. This targeted approach enhances the efficacy of cancer treatment while minimizing side effects. As the pharmaceutical industry continues to focus on precision medicine, ADCs have gained prominence in oncology. The ADC contract manufacturing market plays a key role in this ecosystem, providing specialized services for the development, manufacturing, and testing of ADCs. These services encompass various stages, including antibody production, payload conjugation, formulation, and fill-finish processes. The market is characterized by collaborations and partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs) to leverage expertise and resources, ensuring efficient and cost-effective ADC development and production.
Key factors driving the growth of the ADC contract manufacturing market include the rising incidence of cancer globally, the expanding pipeline of ADC candidates, and advancements in bioconjugation technologies. Additionally, regulatory agencies' increasing acceptance of ADCs and the growing emphasis on personalized medicine contribute to market expansion. Contract manufacturing organizations offer a range of capabilities, from process development to commercial-scale manufacturing, enabling pharmaceutical companies to outsource specific aspects of ADC production. As the demand for ADCs continues to rise, the ADC contract manufacturing market is expected to witness sustained growth, offering opportunities for both established players and new applicants in the biopharmaceutical manufacturing sector.
Major vendors in the global ADC Contract Manufacturing market:
- AbbVie Inc.
- Catalent, Inc.
- LEGOCHEM BIOSCIENCES, Inc.
- Lonza
- MabPlex International Co. Ltd
- Merck KGaA
- Piramal Pharma Solutions
- Recipharm AB
- Samsung Biologics
- Sartorius AG
- Sterling Pharma Solutions Limited
- WuXi Biologics
- Others
Request for Discount @ https://www.marketdigits.com/request/discount/4552
Increasing adoption of ADC therapies
The increasing adoption of ADC (Antibody-Drug Conjugate) therapies is an essential driver propelling the ADC contract manufacturing market into a phase of growth. As the field of oncology witnesses a prominent shift towards precision medicine, ADCs have gained prominence due to their targeted approach in delivering potent cytotoxic agents directly to cancer cells. This adoption is fueled by the desire to enhance treatment efficacy while minimizing adverse effects on healthy tissues, a crucial aspect of cancer therapeutics. With a rising understanding of the molecular details of various cancers, pharmaceutical companies are increasingly investing in the development of ADCs as a cornerstone of their oncology portfolios. The adoption of ADC therapies is particularly evident in clinical trials and the approval of novel drugs by regulatory authorities, reflecting the industry's confidence in the potential of ADCs to address unmet medical needs. This driver is catalyzing collaboration and investment within the pharmaceutical sector, creating a dynamic landscape where ADC contract manufacturing plays a key role in supporting the production of these advanced and targeted therapeutic interventions.
Market Dynamics
Drivers:
- Global increase in cancer cases
- Growing demand for precision medicine in healthcare
- Increasing adoption of ADC therapies
Opportunities:
- The expanding researchers of oncology drugs
- Ongoing advancements in bioconjugation technologies
- Growing emphasis on personalized medicine in the pharmaceutical industry
Ongoing advancements in bioconjugation technologies
The ongoing advancements in bioconjugation technologies present a significant opportunity for the ADC (Antibody-Drug Conjugate) contract manufacturing market. Bioconjugation is a critical aspect of ADC development, involving the precise linkage of cytotoxic payloads to monoclonal antibodies. Recent advances in this field have led to the development of more efficient and sophisticated conjugation methods, allowing for improved control over drug-to-antibody ratios and enhancing the overall therapeutic efficacy of ADCs. New bioconjugation technologies offer greater flexibility in selecting suitable linkers and conjugation chemistries, enabling the creation of ADCs with enhanced pharmacokinetics and reduced toxicity. The increased precision in the conjugation process also contributes to the production of homogeneous ADCs with consistent therapeutic profiles. This improves the safety and efficacy of ADCs and also updates the manufacturing process by reducing the variability associated with drug conjugation. As a result, contract manufacturing organizations specializing in ADCs can capitalize on these technological advancements to offer more healthy and reliable services to pharmaceutical companies. The opportunity lies in leveraging these innovative bioconjugation techniques to produce high-quality ADCs at scale, meeting the growing demand for targeted cancer therapies, and positioning the ADC contract manufacturing market at the forefront of biopharmaceutical manufacturing advancements.
North America dominates the market for ADC contract manufacturing.
North America stands out as the dominating region in the global ADC Contract Manufacturing market, with the U.S. leading in consumption and market share. This region is characterized by high growth attributed to a well-established biopharmaceutical industry, advanced research infrastructure, and a high prevalence of cancer cases. The region is a hub for innovative drug development, fostering strategic collaborations between pharmaceutical companies and ADC contract manufacturing organizations. Regulatory support and a strong emphasis on precision medicine contribute to the market's expansion in North America.
Asia Pacific region is experiencing rapid growth in the ADC contract manufacturing market due to the increasing focus on biopharmaceutical manufacturing in countries like China, India, and Japan. These countries offer a cost-effective manufacturing environment, skilled labor, and a growing pool of contract manufacturing organizations specializing in biologics. Additionally, the rise in cancer incidence, improving healthcare infrastructure, and favorable government initiatives in the Asia Pacific contribute to the market's attractiveness.
Another noteworthy region is the Middle East and Africa, driven by a rising cancer prevalence and increasing healthcare investments. Challenges include limited infrastructure, a shortage of skilled workforce, regulatory complexities, and funding constraints. Overcoming these challenges requires strategic investments in infrastructure, workforce training, regulatory harmonization, and fostering international collaborations to accelerate the region's capabilities in ADC contract manufacturing.
Inquire Before Buying: https://www.marketdigits.com/request/enquiry-before-buying/4552
The cleavable linker segment is anticipated to hold the largest market share during the forecast period
The cleavable linker segment in the ADC contract manufacturing market represents a key element in the development of targeted cancer therapies. Cleavable linkers are chemical bonds designed to connect the cytotoxic payload to the monoclonal antibody within an ADC. These linkers possess the unique ability to break or cleave in response to specific conditions, such as the acidic environment within cancer cells or enzymatic activity, facilitating the release of the potent drug payload at the targeted site. This controlled release mechanism enhances the precision of ADCs, ensuring that the cytotoxic agent is delivered specifically to cancer cells while minimizing off-target effects and reducing systemic toxicity. Contract manufacturing organizations specializing in ADCs play an essential role in the cleavable linker segment, offering expertise in linker chemistry, conjugation techniques, and formulation processes to pharmaceutical companies. The continuous evolution and innovation in cleavable linker technologies contribute to the advancement of ADCs as a promising class of biopharmaceuticals, positioning the cleavable linker segment as a key driver in the dynamic landscape of ADC contract manufacturing.
Segmentations Analysis of ADC Contract Manufacturing Market: -
- By Linker
- Cleavable Linker
- Non-Cleavable Linkers
- Others
- By Application
- Myeloma
- Lymphoma
- Breast Cancer
- Others
- By End User
- Biotechnology Companies
- Pharmaceutical Companies
- Others
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Direct Order Can Be Placed Through This Link and Get 25% Discount on Premium Report: https://www.marketdigits.com/checkout/4552?lic=s
Browse Similar Reports:
Pharmaceutical Contract Manufacturing Market 2023 – 2030 By Biologic, Drug Development, End User, Service- Partner & Customer Ecosystem Competitive Index & Regional Footprints by MarketDigits
Biopharmaceutical Contract Manufacturing Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints by MarketDigits
Biologics Contract Manufacturing Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints by MarketDigits
About MarketDigits:
MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.
We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.
Contact Us:
MarketDigits
1248 CarMia Way Richmond,
VA 23235,
United States.
USA: +1 847 450 0808
Email: sales@marketdigits.com
Web: https://www.marketdigits.com
Follow Us on: | Twitter | LinkedIn |
